Pēdējā atjaunošana :
19/11/2024
Infostab
Saraksti
Kopsavilkums
Meklēt saderības
Y-savienojuma saderības tabula
Literatūras saraksts
pētniecības grupas
valistab
plakāts
Savienojumi
sponsori
Autori
Lietošanas instrukcija
Newsletter
Irinotecan
Ķīmiskā uzbūve
Oriģinālais nosaukums
Tirdzniecības nosaukumi ir apzīmējoši un palīgvielas var atšķirties dažādām valstīm un laboratorijām
Asinib
Meksika
Axinotecan
Vācija
Campto
Apvienotie Arābu Emirāti, Austrija, Beļģija, Dānija, Dienvidāfrikas Republika, Francija, Grieķija, Holande, Horvātija, Indija, Irāna, Īrija, Itālija, Japāna, Lielbritānija, Luksemburga, Malaizija, Maroka, Norvēģija, Polija, Portugāle, Somija, Spānija, Šveice, Taizeme, Tunisija, Turcija, Ungārija, Zviedrija
Camptosar
Amerikas Savienotās Valstis, Brazīlija, Kanāda
Irinoliquid
Austrija
Irnocam
Brazīlija
Literatūras saraksts : Irinotecan
tips
publicēšana
1423
Žurnāls
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1617
Žurnāls
Li WY, Koda RT.
Stability of irinotecan hydrochloride in aqueous solutions.
Am J Health-Syst Pharm 2002 ; 59: 539-544.
1662
Žurnāls
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1918
Žurnāls
Dodds HM, Craik DJ, Rivory LP.
Photodegradation of irinotecan (CPT-11) in aqueous solutions : identification of fluorescent products and influence of solution composition.
J Pharm Sci 1997 ; 86, 12: 1410-1416.
1920
Žurnāls
Akimoto K, Kaway A, Ohya K et al.
Photodegradation reactions of CPT-11, a derivative of campothecion, part i: chemical structure of main degradation products in aqueous solution.
Drug Stability 1996 ; 1: 118-122.
1921
Žurnāls
Akimoto K, Kawai A, Ohya K.
Photodegradation reactions of CPT-11, a derivative of campothecion, part ii: photodegradation behaviour of CPT-11 in aqueous solution.
Drug Stability 1996 ; 1; 141-146.
1953
Žurnāls
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1976
Žurnāls
Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 238-241.
2027
Žurnāls
Walker SE, Shirley L, Puodziunas A.
Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers.
Can J Hosp Pharm 2005 ; 58: 212-222.
2143
Žurnāls
Dodds HM, Robert J, Rivory LP.
The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry.
J Pharm Biomed Anal 1998 ; 17: 785-792.
2168
Žurnāls
Ozdemir FA, Anilanmert B, Pekin M.
Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution.
Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2241
Žurnāls
Thiesen J, Krämer I.
Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags.
J Oncol Pharm Practice 2000 ; 6, 3: 115-121.
2340
Žurnāls
Walker S.E, Law S, Puodziunas A.
Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers
Can J Hosp Pharm 2005 ; 58, 4: 212-222.
2671
Žurnāls
Kaiser J, Thiesen J, Krämer I.
Stability of irinotecan-loaded eluting beads (DC Bead) used for transarterial chemoembolization.
J Oncol Pharm Practice 2010 ; 16: 53-61.
3129
Laboratorija
Irinotécan (Campto®) – Résumé des caractéristiques du produits
Pfizer 2008
3369
Laboratorija
Levofolinate de sodium Medac - Résumé des caractéristiques du produits
MEDAC France 2011
3670
Žurnāls
Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3873
Žurnāls
Tan X, Hu J.
Incompatibility between irinotecan and fluorouracil injections
Am J Health-Syst Pharm 2016 ; 73:755.
Mentions Légales